Bill > A03236

This bill enacts the "New York Affordable Drug Manufacturing Act" to establish a state-level program for producing and distributing generic prescription drugs. The bill directs the New York State Commissioner of Health to enter into partnerships with drug manufacturers to increase competition, lower drug prices, and address shortages in the generic drug market. These partnerships will focus on producing generic drugs that target high-cost and chronic conditions, with a specific requirement to include at least one form of insulin. The bill outlines a detailed process for selecting drugs, including consulting with various public and private purchasers like state agencies, health insurers, and hospitals. When determining drug pricing, the department will consider factors such as FDA user fees, production costs, research and development expenses, and other start-up costs. All state agencies will be required to purchase generic drugs through these departmental partnerships. The bill also mandates two key reports to the legislature: one by January 2028 assessing the feasibility of directly manufacturing generic drugs, and another by March 2027 describing the status of targeted drugs and analyzing the program's potential impact on drug competition and pricing. Importantly, the bill includes a provision to protect any proprietary information obtained during this process from public disclosure.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A3236